New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
07:44 EDTBAX, ONTXRigosertib failure removes positive catalyst for Baxter, says Leerink
Leerink says Onconova's (ONTX) announcement last night that pivotal results of IV rigosertib in myelodysplastic syndrome failed to meet its primary endpoint as removing a positive catalyst for Baxter (BAX) since Baxter has the European rights to rigosertib. Leerink points out that Baxter had previously noted that rigosertib could ultimately be a $1B drug. However, the firm believes rigosertib was largely not reflected in estimates for Baxter and it reiterates an Outperform rating on the stock.
News For BAX;ONTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
10:06 EDTBAXHigh option volume stocks
High option volume stocks: GLOG ACI NGD BEAT BAX TTPH STJ FNF SSTK
06:11 EDTONTXOnconova applies for European Phase 3 clinical trial for rigosertib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use